Prometheus Biosciences: Jumps in Nasdaq debut

Prometheus Biosciences

12/03/2021 17:11

** Shares of biotech co Prometheus Biosciences Inc  RXDX.O 
jump more than 31% after their stock market debut 
    ** Shares opened at $24.95; co's IPO was priced at $19 per
share
    ** At the opening price, co was valued at around $904.5 mln
    ** Co offered 10 mln shares in IPO, raising about $190 mln
    ** Prometheus is engaged in the discovery and development of
therapeutic and diagnostic products for treatment of
inflammatory bowel disease (IBD)
    ** SVB Leerink, Credit Suisse, Stifel and Guggenheim
Securities were the joint bookrunning managers for RXDX's
offering

 (Reporting by Sohini Podder in Bengaluru)
 ((sohini.podder@thomsonreuters.com))